Publicaciones de Jorge Federico Elgart

2017

  • Relation between cost of drug treatment and body mass index in people with type 2 diabetes in Latin America. Elgart JF, Prestes M, Gonzalez L, Rucci E, Gagliardino JJ; QUALIDIAB Net study group. PLoS One. 2017 Dec 20;12(12):e0189755. doi: 10.1371/journal.pone.0189755.
  • Health inequalities and the impact on the prevalence of cardiovascular risk factors and chronic complications in Argentina: a study on national risk factors surveys. Asteazaran S, Gagliardino JJ, Elgart JF. Medwave. 2017 Nov 27;17(9):e7083. doi:10.5867/medwave.2017.09.7083.
  • Improving diabetes care at primary care level with a multistrategic approach: results of the DIAPREM programme. Prestes M, Gayarre MA, Elgart JF, Gonzalez L, Rucci E, Paganini JM, Gagliardino JJ; DIAPREM (DIAbetes Primary Care, Registry, Education and Management). Acta Diabetol. 2017 Jun 17. doi: 10.1007/s00592-017-1016-8.
  • Multistrategic approach to improve quality of care of people with diabetes at the primary care level: Study design and baseline data. Prestes M, Gayarre MA, Elgart JF, Gonzalez L, Rucci E, Gagliardino JJ; DIAPREM (DIAbetes Primary Care, Registry, Education and Management). Prim Care Diabetes. 2017 Apr;11(2):193-200.
  • Evolución de la Calidad de Atención en personas con Diabetes Tipo 2 (DMT2) de Argentina: Resultados del International Diabetes Management Practices Study (IDMPS). Elgart JF, Forti L, De Luca J, Guaita MS, Gagliardino JJ. ISPOR 6th Latin America Conference (Sao Pablo, Brasil). Value in Health, 2017; 20(9):A921–A922.
  • Costo Medico Directo Atribuible al tratamiento de pacientes con Neoplasia Intraepitelial Cervical (CIN) 2 Morfológico e impacto económico del diagnóstico diferencial con Biomarcador P16 en una Institución Privada de la Ciudad De Buenos Aires. Elgart JF, Fishkel V, von Petery F, Peña T, Torres F, Avagnina A, Monge F, Denninghoff V. ISPOR 6th Latin America Conference (Sao Pablo, Brasil). Value in Health, 2017; 20(9):A924.
  • Resultados de la Implementación de una estrategia combinada de Educación y Gestión de Pacientes en Centros de Atención Primaria de Argentina. Prestes M, Gayarre MA, Elgart JF, Rucci E, Paganini JM, Gagliardino JJ. ISPOR 6th Latin America Conference (Sao Pablo, Brasil). Value in Health, 2017; 20(9):A857–A858.
  • Clinical-metabolic characteristics of people with Type 2 Diabetes in Argentina: Results from the 2006-2012 International Survey of Diabetes Management Practices (IDMPS). Gagliardino JJ, Elgart J, Forti L, Guaita S, De Luca J. 4th Latin America CODHy Congress. Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). 2017.
  • International Diabetes Management Practice Survey (IDMPS): Determinants for achieving therapeutic goals in people with Type 2 Diabetes in Argentina. Gagliardino JJ, Elgart J, Forti L, Guaita S, De Luca J. 4th Latin America CODHy Congress. Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). 2017.

2016

  • Frequency of self-monitoring blood glucose and attainment of HbA1c target values. Elgart JF, González L, Prestes M, Rucci E, Gagliardino JJ. Acta Diabetologica. Feb; 53(1):57-62. doi: 10.1007/s00592-015-0745-9 (ISSN: 0940-5429).
  • Primary prevention of type 2 diabetes in Argentina: Pilot study in the province of Buenos Aires. Juan José Gagliardino, Graciela Etchegoyen, Marcelo Bourgeois, Gabriel Fantuzzi, Silvia García, Lorena González, Jorge Federico Elgart, Matías Ré, Alberto Ricart, Juan Pablo Ricart, Eduardo Spinedi. Revista Argentina de Endocrinología y Metabolismo 53:135-141, 2016.
  • Dapagliflozin versus Sulfonylurea as an add-on therapy to Metformin: a Cost-effectiveness analysis in Costa Rica. Elgart JF, Gonzalez L, Prestes M, Vinocour M, Solorzano J, Gagliardino JJ. ISPOR 21st International Meeting, Washington, USA. Value in Health. 2016; 19(3):A202.
  • Cost-effectiveness of Dapagliflozin in the treatment of type 2 diabetes mellitus in Peru. Elgart JF, Gonzalez L, Prestes M, Manrique H, Solorzano J, Gagliardino JJ. ISPOR 21st International Meeting, Washington, USA. Value in Health. 2016; 19(3):A203.
  • Cost of type 2 diabetes treatment in Latin America: effect of degree of metabolic control. Elgart JF, Gonzalez L, Prestes M, Gagliardino JJ. ISPOR 21st International Meeting, Washington, USA. Value in Health. 2016; 19(3):A201.
  • Dapagliflozin: Cost effectiveness as an add-on therapy to metformin in the treatment of type 2 diabetes in Ecuador. Elgart JF, Prestes M, Gonzalez L, Solis Sanchez C, Acosta W, Solorzano J, Gagliardino JJ. ISPOR 21st International Meeting, Washington, USA. Value in Health. 2016; 19(3):A202.
  • Resultados preliminares del programa piloto de prevención primaria de diabetes en la Provincia de Buenos Aires (PPDBA). Gagliardino J, Etchegoyen G, Spinedi E, Bourgeois M, Elgart J, Fantuzzi G, García S, González C, González L, Re M, Ricart A, Ricart J. XX Congreso Argentino de Diabetes, Sociedad Argentina de Diabetes (SAD). Revista de la SAD. 2016.
  • Impacto del grado de control metabólico sobre el costo del tratamiento Farmacológico de la diabetes tipo 2 en Argentina. Elgart JF, González L, Prestes M, Gagliardino JJ. XX Congreso Argentino de Diabetes, Sociedad Argentina de Diabetes (SAD). Revista de la SAD. 2016.
  • Cost-effectiveness of dapagliflozin as an add-on therapy to metformin in the treatment of type 2 diabetes (T2DM) in the Dominican Republic and Guatemala. Elgart JF, Prestes M, Gonzalez L, Solorzano J, Gagliardino JJ. ISPOR 19th Annual Europena Congress. Value in Health, 2016; 19(7):A671–A672.

2015

  • Educación de personas con diabetes tipo 2: ¿Es costo efectiva su implementación a través de pares con diabetes?. Gonzalez L, Elgart JF, Gagliardino JJ. Medwave Medwave. Dec; 15(11):e6348. doi: 10.5867/medwave.2015.11.6348 (ISSN: 0717-6384).
  • Análisis de Costo-Efectividad de la Educacion de pacientes con Diabetes Tipo 2 por Pares. Gonzalez L, Elgart JF, Prestes M, Gagliardino JJ. ISPOR 5th Latin America Conference, Santiago, Chile. Value in Health. 2015; 18(7):A864-865
  • Impacto Presupuestario de Incorporar Linagliptina para el tratamiento de la Diabetes en Argentina. Elgart JF, Prestes M, Gonzalez L, De los Santos MC, Gagliardino JJ. ISPOR 5th Latin America Conference, Santiago, Chile. Value in Health. 2015; 18(7):A863
  • Body mass index impact on treatment costs in people with type 2 diabetes in Latin America. Elgart JF, Gonzalez L, Rucci E, Gagliardino JJ. IDF World Diabetes Congress, Vancouver, Canadá.

2014

  • Association between socioeconomic status, type 2 diabetes and its chronic complications in Argentina. Elgart JF, Caporale JE, Asteazarán S, De La Fuente JL, Camilluci C, Brown JB, González CD, Gagliardino JJ. Diabetes Res Clin Pract. 2014;104(2):241-7. doi: 10.1016/j.diabres.2014.02.010.
  • Calidad de atención de personas con diabetes tipo 2 en Latinoamérica: ¿hay evidencia de disparidad de género? Wandurraga EA, Villena Chávez J, Stepenka V, Solis CL, Ramirez de Peña D, Perez Manghi F, Padron MA, Manrique H, Lujan D, Lapertosa S, Gonzalez J, Fuente G, Faingold MC, Commendatore V, Aschner P, Gonzalez L, Elgart JF, Gagliardino JJ, DIFAR Academic Committee. Revista ALAD Vol 4 Nº 3. 2014.
  • Direct and indirect costs associated to type 2 diabetes and its complications measured in a social security institution of Argentina. Elgart J; Asteazaran S; de la Fuente J; Camillucci C; Brown JB; Gagliardino JJ. International journal of public health Basel: Birkhauser Verlag AG, 2014. vol. 59, p. 851-857. ISSN 1661-8556
  • Automonitoreo glucémico: utilización y costo según tipo de medicación y grado de control metabólico en la seguridad social argentina. Gonzalez Lorena; Elgart Jorge; Rucci Enzo; Prestes Mariana; Gagliardino JJ. Resumen. Congreso. XIX Congreso Argentino de Diabetes, Sociedad Argentina de Diabetes (SAD). Mar del Plata. 2014.
  • Calidad de atención de personas con diabetes tipo 2 en argentina (QUALIDIAB): ¿Prescribimos y logramos metas terapéuticas recomendadas en nuestros pacientes?. Faingold MC; Lapertosa S; Fuente G; Perez Manghi F; Gonzalez J; Commendatore V; De Carolis S; Rueda S; Urdangarin R; Sosa L; Gonzalez Lorena; Elgart Jorge; Gagliard
  • Dapagliflozin versus sulfonylurea as an add-on therapy to metformin: a cost-effectiveness analysis in Colombia. Elgart Jorge; Prestes Mariana; Gonzalez Lorena; Aschner P; Garrido Lecca S; Aiello Eleonora; Jimenez C; Gagliardino JJ. Resumen. Congreso. ISPOR 19th International Meeting. 2014.
  • Saxagliptin/metformin extended-release (xr) for the type 2 diabetes (T2DM) treatment in Venezuela: a budget impact analysis. Elgart Jorge; Gonzalez Lorena; Perez Monteverde; Garrido Lecca S; Aiello Eleonora; Gagliardino JJ. Resumen. Congreso. ISPOR 19th International Meeting, Montreal, Canadá. 2014.
  • Treatment of type 2 diabetes in Colombia: economic evaluation of Saxagliptin/Metformin extended-release (xr) fixed-dose combination (FDC). Elgart Jorge; Prestes Mariana; Gonzalez Lorena; Garrido Lecca S; Aiello Eleonora; Jimenez C. Resumen. Congreso. ISPOR 19th International Meeting, Montreal, Canadá. Value in Health. 2014.
  • Self-Monitoring of Blood Glucose: use, frequency drivers, and cost in Argentina. Jorge Elgart; Lorena Gonzalez; Enzo Rucci; Juan José Gagliardino. Journal of diabetes Science and technology California: SAGE Journals, 2014. vol. 8, n° 6, p. 1121-1125. ISSN 1932-2968
  • The Burden of Diabetes in Argentina. Gonzalez Lorena; Caporale Joaquín; Elgart Jorge; Gagliardino JJ. Global journal of health Science. Canadian Center of Science and Education, 2014. vol. 7, n° 3, p. 124-133. ISSN 1916-9736
  • Dapagliflozin: cost-effectiveness as an add-on therapy to metformin in the treatment of type 2 diabetes (T2DM) in Argentina and Chile. Elgart JF, Prestes M, Gonzalez L, Asteazaran S, Aiello E, Garrido Lecca S, Alvarez A, Roberts M, Cortes Cuadra P, Gagliardino JJ. ISPOR 19th International Meeting, Montreal, Canadá. Value in Health. 2014; 17(3):A248.
  • Costos Directos e Indirectos asociados a la Diabetes Tipo 2 y sus complicaciones medidos en la Seguridad Social. Elgart J, Asteazaran S, De La Fuente J, Camillucci C, Gagliardino JJ. XIX Congreso Argentino de Diabetes, Sociedad Argentina de Diabetes (SAD). Revista de la SAD. 2014; 48:60-61.